Shigella vaccines are designed to prevent Shigella infection caused by Shigella bacteria. Shigella bacteria spread through contaminated food and water and cause shigellosis. Shigella vaccines target four groups or serotypes, S. flexneri, S. sonnei, S. boydii and S. dysenteriae, responsible for shigellosis disease. S. flexneri and S. sonnei account for a major share of shigellosis cases globally.

The Shigella vaccines market is estimated to be valued at US$ 574.20 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The Shigella vaccines market is driven by increasing incidence of shigellosis across the globe. As per World Health Organization (WHO), it is estimated that there are over 165 million cases of shigellosis worldwide each year. Shigellosis is most endemic in low income and developing countries. Children under 5 years of age are at major risk of shigellosis which may lead to death or serious health complications. Development of effective Shigella vaccines is expected to control the burden of shigellosis disease which drives their demand.

SWOT Analysis
Strength: Shigella vaccines have strong potential to prevent the spread of shigellosis effectively. It can help reducing antibiotic resistance. Widespread adoption of shigella vaccines can help controlling the disease globally.
Weakness: High development costs and regulatory hurdles associated with vaccines development poses challenges. Limited understanding of immune response for shigella poses difficulties in vaccine design.
Opportunity: Increasing incidence of drug resistance shigella strains creates needs for alternative prevention strategies like vaccines. Emerging economies with poor sanitation provides major market opportunites.
Threats: Long immunization timelines compared to other interventions can slow adoption. Other low-cost treatment options availability can impact vaccine uptake.

Key Takeaways

The global Shigella vaccines market is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing incidence of drug resistant Shigella strains.

Regional analysis:
Asia Pacific region is fastest growing market for Shigella vaccines attributing to large population base and poor sanitation conditions in many countries which increases disease risk. North America dominated the global market in 2023 owing to high adoption of advanced vaccines and presence of major players.

Key players:
Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. MSD Wellcome Trust Hilleman Laboratories leads the clinical research for candidate Shigella vaccine.